Aardvark Therapeutics, Inc. (AARD) FinancialsAARDAardvark Therapeutics, Inc.

Evaluating the bottom line, Aardvark Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -66.02%, provide a clear picture of how effectively AARD converts its operational activities into shareholder value.

In the context of the broader market, AARD competes directly with industry leaders such as MGX and ALGS. With a market capitalization of $23.64M, it holds a significant position in the sector. When comparing efficiency, AARD's gross margin of N/A stands against MGX's 100.00% and ALGS's 100.00%. Such benchmarking helps identify whether Aardvark Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Aardvark reported a net loss of $14.4 million in Q2 2026, unchanged from Q2 2025, indicating persistent financial pressures. The company has a current ratio of 12.63, showing good liquidity, but the overall equity is negative at -$74.8 million.